Multi-omics Biomarker Analysis Identifies Unique Immune Activation Signature in Pancreatic Cancer

We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.